Undisclosed Program (GFS)
Glaucoma Filtration Surgery
Pre-clinical / ClinicalIn pipeline
Key Facts
Indication
Glaucoma Filtration Surgery
Phase
Pre-clinical / Clinical
Status
In pipeline
Company
About Cloudbreak Pharmaceutical
Founded in 2015 and headquartered in Irvine, California, Cloudbreak Pharmaceutical is a global biotech focused on transforming ophthalmic care through innovative drug development. The company has advanced its lead asset, CBT-001, into Phase 3 trials following a successful End-of-Phase 2 meeting with the FDA, positioning it as a potential first therapeutic for pterygium. Cloudbreak's strategy combines in-house R&D expertise with strategic regional partnerships, including agreements with Santen and Grand Pharma, to develop and commercialize its pipeline across major markets.
View full company profile